Epoch Health112,000 Bottles of Heart and Blood Pressure Drugs Under Recall, Says FDA

The FDA issued a Class II recall of 112,327 bottles of Teva-manufactured metoprolol succinate ER across all four strengths (25, 50, 100, 200 mg) due to failed dissolution specifications, meaning the drug may not break down efficiently in the body. Metoprolol succinate is the sixth-most prescribed drug in the US, with nearly 59.5 million prescriptions filled in 2023 alone.

⚖️ Professional Impact

• Failed dissolution means patients with heart failure, hypertension, or angina may have received subtherapeutic dosing without knowing
• AF patients recently switched to metoprolol to avoid diltiazem’s bleeding risk may be on recalled lots requiring immediate verification
• This is the second metoprolol succinate recall in 12 months, following Granules Pharmaceuticals’ 33,000-bottle recall for the same dissolution failure
• Teva issued no press release; patients are unlikely to be aware without direct physician or pharmacy outreach

🎯 Action Items

• Verify current patient prescriptions against recalled lot numbers on the FDA website
• Contact patients on recalled lots, particularly those with heart failure or recent ACS
• Coordinate with pharmacies to confirm dispensing status of affected lot numbers
• Document all patient notifications and prescription substitutions in the medical record

More Product Recalls